CLINICAL TRIALS PROFILE FOR DELGOCITINIB

All Clinical Trials for DELGOCITINIB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03683719 ↗	Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema	Completed	LEO Pharma	Phase 2	2018-11-28	The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema. This was judged by a range of assessments that rate the severity and extent of chronic hand eczema and its symptoms, as well as general health status and quality of life.
NCT03725722 ↗	Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.	Completed	LEO Pharma	Phase 2	2018-12-28	This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe atopic dermatitis (AD).
NCT03826901 ↗	Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children	Completed	LEO Pharma	Phase 1	2019-02-20	This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
NCT03958955 ↗	Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.	Terminated	LEO Pharma	Phase 2	2019-07-09	This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase 2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream in the treatment of adult subjects with discoid lupus erythematosus (DLE).
NCT04361136 ↗	Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream	Completed	LEO Pharma	Phase 1	2020-04-23	This is a single-centre, randomised, vehicle-controlled, double-blind, within-subject comparison phase 1 clinical trial. The trial is designed to find out if delgocitinib cream can cause skin irritation after light exposure in people with healthy skin.
NCT04807751 ↗	Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream	Completed	LEO Pharma	Phase 1	2021-03-25	Participants will have study medicine applied by site staff- delgocitinib cream or vehicle, and then exposed to UV light. The trial is designed to find out if delgocitinib cream can cause skin photoallergy after UV-light exposure in people with healthy skin.

Clinical Trial Conditions for DELGOCITINIB

Condition Name

Condition Name for DELGOCITINIB
Intervention	Trials
Chronic Hand Eczema	8
Healthy Volunteers	3
Atopic Dermatitis	2
Frontal Fibrosing Alopecia	1

Condition MeSH

Condition MeSH for DELGOCITINIB
Intervention	Trials
Eczema	10
Dermatitis, Atopic	2
Dermatitis	2
Lupus Erythematosus, Discoid	1

Clinical Trial Locations for DELGOCITINIB

Trials by Country

Trials by Country for DELGOCITINIB
Location	Trials
United States	32
Canada	22
France	9
Germany	8
United Kingdom	6

Trials by US State

Trials by US State for DELGOCITINIB
Location	Trials
California	4
New York	3
Pennsylvania	2
Michigan	2
Illinois	2

Clinical Trial Progress for DELGOCITINIB

Clinical Trial Phase

Clinical Trial Phase for DELGOCITINIB
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	1
Phase 3	6

Clinical Trial Status

Clinical Trial Status for DELGOCITINIB
Clinical Trial Phase	Trials
Completed	5
Recruiting	5
Not yet recruiting	4

Clinical Trial Sponsors for DELGOCITINIB

Sponsor Name

Sponsor Name for DELGOCITINIB
Sponsor	Trials
LEO Pharma	17
Aalborg University	1

Sponsor Type

Sponsor Type for DELGOCITINIB
Sponsor	Trials
Industry	17
OTHER	1

Delgocitinib: Clinical Trials Update, Market Analysis, and Projection

Last updated: March 8, 2026

What is the current status of delgocitinib in clinical development?

Delgocitinib is a topical Janus kinase (JAK) inhibitor developed by Japan Tobacco Inc. (JT) for dermatological conditions. It targets inflammatory pathways implicated in atopic dermatitis (AD), psoriasis, and other immune-mediated skin diseases.

Clinical Trial Phases and Outcomes

• Phase 3 Trials (AD): Completed in Japan with positive results indicating significant efficacy in reducing symptoms of moderate-to-severe AD. JT reported primary endpoints were met, including improvements in Eczema Area and Severity Index (EASI) scores and patient-reported outcomes.
• Phase 2 Trials (Atopic Dermatitis): Showed promising safety and efficacy profiles. A prominent trial published in 2021 demonstrated statistically significant improvements over placebo.
• Other Indications: Trials for psoriasis and chronic hand eczema are ongoing or planned, reflecting broad application potential.

Regulatory Status

• Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved delgocitinib for atopic dermatitis in 2021 under a special regulatory pathway.
• No approval or filings pending in China, EU, or US as of early 2023.

Market landscape and competitive positioning

Market Size

• Atopic Dermatitis (AD): Global market valued at $4.4 billion in 2022, projected to grow at approximately 10% CAGR through 2030[1].
• Psoriasis: Market estimated at $4.0 billion in 2022, with JAK inhibitors increasingly used as targeted therapies[2].

Key competitors

Drug Name	Class	Indication	Approval Status	Estimated Revenue (2022)
Ruxolitinib	Oral JAK1/2 inhibitor	Myelofibrosis, AD, PV	Approved in US (oral)	$700 million[3]
Baricitinib	Oral JAK1/2 inhibitor	Rheumatoid arthritis, AD	Approved in US, EU	$1.4 billion[4]
Crisaborole	PDE4 inhibitor	AD (topical)	Approved globally	$700 million[5]
Delgocitinib	Topical JAK inhibitor	AD (Japan)	Approved in Japan	N/A (marketed only in Japan)

Market Position of Delgocitinib

• First topical JAK inhibitor approved specifically for AD in Japan.
• Competitive advantage in Japan: topical administration with known safety profile and efficacy.
• Limited penetration outside Japan currently restricts global market share.

Market projection and growth opportunities

Revenue projections

• Short term (2023-2025): Estimated modest sales in Japan, reaching approximately $200 million annually by 2025 as awareness and physician adoption increase.
• Mid term (2026-2030): Potential expansion to China, South Korea, and Southeast Asia, where dermatology markets are expanding rapidly, could boost revenues to approximately $1 billion globally if approved and marketed effectively.

Regulatory and commercialization strategies

• Expanding indications: Trials for psoriasis and other inflammatory skin conditions could increase application scope.
• Global regulatory filings: Submission plans to FDA and EMA are under consideration but are not confirmed.
• Partnerships: Potential licensing or co-development deals with global pharma firms could accelerate market entry and sales.

Challenges

• Delays in global approval processes.
• Competition from established global brands like Ruxolitinib, Baricitinib, and PDE4 inhibitors.
• Pricing pressures, especially in Europe and North America.

Key considerations for investors and R&D planners

• Monitoring clinical trial progress, particularly for psoriasis and other indications.
• Evaluating potential for strategic licensing deals to enhance global footprint.
• Assessing reimbursement landscape and pricing strategies in key markets.

Key Takeaways

• Delgocitinib is approved solely in Japan for AD, with positive Phase 3 results supporting further development.
• Market potential is significant in Japan and Asia but limited elsewhere at present.
• Revenue projections depend on regulatory expansion and global market penetration over the next five years.
• Competition remains strong; success hinges on demonstrating clear advantages over existing therapies.
• Ongoing trials may unlock additional indications, broadening market opportunity.

FAQs

1. When will delgocitinib seek approval outside Japan?
No formal plans announced; regulatory filings in the US or EU are yet to be confirmed.

2. How does delgocitinib compare to other JAK inhibitors?
It is a topical formulation, potentially offering a safer profile with fewer systemic side effects compared to oral JAK inhibitors like Ruxolitinib or Baricitinib.

3. What are the main safety concerns?
Clinical trials indicate a favorable safety profile, with mild to moderate application site reactions being most common, similar to other topical JAK inhibitors.

4. Can delgocitinib expand into other indications?
Yes. Trials for psoriasis and chronic hand eczema are ongoing or planned, which could diversify revenue streams.

5. What factors influence delgocitinib’s market success?
Regulatory approvals outside Japan, effective reimbursement strategies, competitive differentiation, and clinical efficacy in broader populations.

---

References
[1] Grand View Research. (2022). Atopic dermatitis market size & trends.
[2] GlobalData. (2022). Psoriasis market analysis.
[3] IQVIA. (2022). Ruxolitinib sales data.
[4] EvaluatePharma. (2022). Baricitinib revenue estimates.
[5] Fosun Pharma. (2022). Crisaborole sales figures.